Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBI 0201-ESO TCRT in NY-ESO-1+ Metastatic Cancers
NCT05296564Phase 2Recruiting
- Sponsor
- Hadassah Medical Organization
- Start
- Apr 2022
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HBI0201-ESO in synovial sarcoma (SS), soft tissue sarcoma (STS), melanoma and 5 more, sponsored by Hadassah Medical Organization. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 5 years and Objective Tumor Regression at 5 years. Started Apr 2022; status: recruiting.
02
Drugs
HBI0201-ESO
03
Conditions
synovial sarcoma (SS)soft tissue sarcoma (STS)melanomatriple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05296564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05296564.